Core Viewpoint - The article discusses the role of Fibroblast Growth Factor 21 (FGF21) in the context of heart failure with preserved ejection fraction (HFpEF), highlighting its mechanism of action through inter-organ communication and its potential as a therapeutic target in cardiovascular metabolic diseases [4][5]. Group 1: FGF21's Inter-Organ Communication Effects - FGF21 plays a crucial role in regulating mitochondrial energy metabolism through the adipose-heart axis, which is essential for improving HFpEF [4]. - The protective effects of FGF21 on the heart are dependent on the adiponectin (APN) signaling pathway [5]. Group 2: Biological Functions of FGFs and Drug Development - The article emphasizes the diverse biological functions of FGFs, particularly FGF21, in maintaining metabolic homeostasis, including blood glucose and blood pressure regulation, and its implications for drug development targeting cardiovascular metabolic diseases [5][15]. Group 3: Insights into Protein Drug Development - The discussion includes the clinical translation challenges in the development of protein drugs based on FGF signaling pathways, indicating a need for innovative approaches in this area [5][15]. Group 4: Event Announcement - An upcoming lecture featuring researcher Lin Zhuofeng will delve into the inter-organ communication mechanisms of FGF21 and its implications for cardiovascular metabolic diseases, along with insights into drug development prospects [5][12].